mRNA

#Eye health #Immunology / Virology & Vaccines #LIfT BioSciences #mRNA

New DDW Highlights podcast: 11 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the week that the US… Read More

#News

Vaccine production
#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #United States

US cancels mRNA vaccine development contracts

The US Department of Health and Human Services (HHS) has announced the beginning of a “coordinated wind-down” of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA).   The department says the decision follows a comprehensive review of mRNA-related investments initiated during the… Read More

#News #Trending News

#mRNA #Partnership #Sartorius #Sensible Biotechnologies

Partnership to scale cell-based mRNA platform

Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding (MoU) to jointly advance the industrialisation and scale-up of Sensible’s first-in-class cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. The collaboration aims to enable clinical-grade production of cell-based mRNA by 2026 and unlock the “next… Read More

#News

mRNA
#Adaptvac #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #University of Copenhagen

Virus-like particles enhance effect of mRNA vaccines

Researchers from Denmark have demonstrated that a simple addition to mRNA vaccines can significantly enhance their effectiveness.  mRNA technology is highly effective against viruses and quick to adapt to new variants, but the immunity tends to wane rapidly, leaving people vulnerable to reinfection just months after vaccination. Read More

#Editor's Choice #News

#BioNTech #CureVac #Immunotherapy #Mergers and acquisitions #mRNA #Oncology

BioNTech boosts mRNA expertise with CureVac acquisition

Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac.  With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies.  The company’s oncology strategy focuses on two pan-tumour programmes, mRNA-based cancer… Read More

#Business & Investment #News

HIV cell
#HIV #Lipid based nanoparticle (LNP) #mRNA #University of Melbourne

New nanoparticle design inspires hopes of HIV cure

Researchers from the Peter Doherty Institute for Infection and Immunity in Melbourne have demonstrated a way to make HIV visible, paving the way to a complete cure. In a paper published in Nature Communications, the scientists have shown for the first time that… Read More

#Editor's Choice #News

Liver cancer
#Moderna #mRNA #Oncology #Phase I trial #Solid tumours

Pan-tumour antigen therapy candidate enters the clinic

The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours.  The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More

#Cancer Research #News

Influenza virus
#Collaboration #Ethris #Lonza #mRNA #mRNA-based vaccines #Respiratory

Partners develop non-invasive mRNA vaccines

Ethris and Lonza have announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates.  The vaccines are designed for mucosal delivery and offer a promising approach to combat respiratory diseases.  Room-temperature stability aims to address significant supply chain challenges associated with some… Read More

#News

#Fast Track designation #FDA #mRNA #Sanofi #Vaccines

Chlamydia vaccine candidate granted fast track designation

The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need.  The chlamydia vaccine candidate… Read More

#News #Regulatory

Gene editing
#Base editing #Beam Therapeutics #Clinical trial #Gene editing #Gene therapy #mRNA

First clinical genetic correction of a disease-causing mutation reported

Biotechnology company Beam Therapeutics says initial data from its Phase I/II trial establish clinical proof-of-concept for BEAM-302 as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.  Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was… Read More

#Editor's Choice #News

Strand of RNA
#Manufacturing #mRNA #Nanopore sequencing #Sitting Down With podcast

Nano Insights: Unveiling the role of mRNA analytics in cGMP manufacturing with Lonza and beyond

In this sponsored DDW Sitting Down With podcast we speak to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. We discuss how nanopore sequencing will… Read More

#Podcasts

Strand of RNA
#Interview #Manufacturing #mRNA #Nanopore sequencing #Sitting Down With podcast

Podcast: Unveiling the role of mRNA analytics in cGMP manufacturing

A new sponsored DDW Sitting Down With podcast is now available. In this podcast, Megan Thomas speaks to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. Read More

#News

mRNA
#Circio Holding #circular RNAs #DNA #Funding #mRNA #Norway #RNA #Viral vectors

NOK 10.7 million supports circular mRNA technology

Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology. The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and… Read More

#News

DDW mRNA eBook cover
#eBook #mRNA #mRNA-based vaccines #RNA #tRNA

mRNA: Uses and innovation for this technology in drug discovery

This eBook, sponsored by Promega, examines the latest innovations that are driving the mRNA drug discovery and development market. Download this exclusive eBook to learn more about: Recent developments in mRNA drug discovery Using AI to design RNA-based medicines The evolution of the RNA therapeutics landscape Using tRNA to treat… Read More

#DDW eBooks #Intelligence

#eBook #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #RNA #tRNA

eBook: mRNA innovation in drug discovery

The success of mRNA-based vaccines for Covid-19 pushed messenger RNA into the spotlight. However, its uses in drug discovery and development aren’t just confined to vaccines – applications include personalised medicine and therapeutics, for example. This eBook, sponsored by Promega, examines the latest innovations that are… Read More

#News

#CRISPR #DNA #Gene editing #mRNA #Proteins #SCIEX

Gene therapy: The quest for cures requires analytics to keep up

This article is sponsored by SCIEX. A new era of medicine has entered clinics with drugs against sickle cell anaemia or gene-related deafness, and many more gene therapy drugs are in different stages of development. These novel approaches go beyond treating symptoms; they aim to cure diseases. However, the diversity… Read More

#News